ReviewPharmacology & therapeutics2019
Cellular determinants and therapeutic implications of inflammation in pancreatic cancer.
Review in Pharmacology & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Global research trends and hotspots in prognostic prediction models for pancreatic cancer: a bibliometric analysis.Frontiers in oncology · 2025Pooled it
- Pooled it
- Dietary inflammatory index and pancreatic cancer risk: a systematic review and dose-response meta-analysis.Public health nutrition · 2021Pooled it
- Diagnostic value of combining preoperative inflammatory markers ratios with CA199 for patients with early-stage pancreatic cancer.BMC cancer · 2023Trial
- Unravelling the pathogenesis and therapeutic approaches of pancreatic ductal adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Article
- The interactions between geriatric nutritional risk index and systemic immune-inflammation index for post-recurrence prognosis in patients with pancreatic cancer: a retrospective study.World journal of surgical oncology · 2026Article
- Multimodal profiling of pancreatic cancer reveals a TIMP-1-dominated secretory profile determining pro-tumor immunoinstruction in human cancers.Cell reports. Medicine · 2026Article
- Research progress on the influence of tumor microenvironment on immunotherapy for pancreatic ductal adenocarcinoma.Open medicine (Warsaw, Poland) · 2026Review
- Co-treatment of ticagrelor and anti-PD-1 immunotherapy in tumor-associated macrophages reduces pancreatic cancer cell growth and migration through the TGF-β1/Smad2 pathway.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Article
- Neutrophil Dynamics Contribute to Disease Progression and Poor Survival in Pancreatic Cancer.Cancers · 2025Article
- Single-cell transcriptome analysis identifies MIF as a novel tumor-associated neutrophil marker for pancreatic ductal adenocarcinoma.NPJ precision oncology · 2025Article
- Predictive value of the monocyte-to-high-density lipoprotein ratio in the prognosis of non-small cell lung cancer patients after surgery.Translational lung cancer research · 2025Article
- Utilizing Albumin Value, HALP Score and LCR Value for Predicting Survival in Patients with Pancreatic Adenocarcinoma.Medicina (Kaunas, Lithuania) · 2025Article
- [Therapeutic mechanism of aqueous extract ofNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Hepatocytes coordinate immune evasion in cancer via release of serum amyloid A proteins.Nature immunology · 2024Article
- New avenues for the treatment of immunotherapy-resistant pancreatic cancer.World journal of gastrointestinal oncology · 2024Review
- Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma.Frontiers in immunology · 2024Review
- Unveiling the immunosuppressive landscape of pancreatic ductal adenocarcinoma: implications for innovative immunotherapy strategies.Frontiers in oncology · 2024Review
- Identifying Effective Biomarkers for Accurate Pancreatic Cancer Prognosis Using Statistical Machine Learning.Diagnostics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Inflammation is a hallmark of cancer. For pancreatic ductal adenocarcinoma (PDAC), malignant cells arise in the context of a brisk inflammatory cell infiltrate surrounded by dense fibrosis that is seen beginning at the earliest stages of cancer conception. This inflammatory and fibrotic milieu supports cancer cell escape from immune elimination and promotes malignant progression and metastatic spread to distant organs. Targeting this inflammatory reaction in PDAC by inhibiting or depleting pro-tumor elements and by engaging the potential of inflammatory cells to acquire anti-tumor activity has garnered strong research and clinical interest. Herein, we describe the current understanding of key determinants of inflammation in PDAC; mechanisms by which inflammation drives immune suppression; the impact of inflammation on metastasis, therapeutic resistance, and clinical outcomes; and strategies to intervene on inflammation for providing therapeutic benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.